Table 1. Clinical application of HSCs or MNCs in patients with ESLD.

Authors	Disease	Cell therapy	Source of MSCs	Dose of injection	Way of injection	No. patients	Outcome
Salama et al. (24)	End stage liver disease	Autologous CD34+ CD133+stem cell	Bone marrow	0.5×108 cells	Portal vein	90	Improvement of liver function
Gordon et al. (25)	Chronic liver failure	Autologous CD34+ stem cell	Peripheral blood	1×106 to 2×108	Portal vein or hepatic artery	5	Improvement of ALB and bilirubin
Newsome et al. (28)	Liver cirrhosis	Autologous CD133+ stem cell	Peripheral blood	0.2×106/kg	Peripheral vein	26	No evidence of the improvement of liver function and MELD score
Bai et al. (29)	Decompensated cirrhosis	Autologous MNCs	Bone marrow	Unclear	Hepatic artery	32	Improvement of liver function and reduction of the incidence of serious complications
Terai et al. (30)	Liver cirrhosis	Autologous MNCs	Bone marrow	(5.20±0.63)×108 cells	Peripheral vein	9	Improvement of ALB and Child-Pugh scores

HSCs, hematopoietic stem cells; ESLD, end-stage liver disease; ALB, albumin; MNCs, mononuclear cells; MELD, model for end-stage liver disease.